Karl-Erik Andersson, MD
Karl-Erik Andersson, MD, Professor
Dr. Karl-Erik Andersson was born and raised in Sweden. He received his medical degree from the University of Lund in 1968, where he subsequently worked as a lecturer in Clinical Pharmacology. He completed his Ph.D. at the Department of Pharmacology, Lund University, in 1973. In 1975 he obtained a Swedish specialist degree in Internal Medicine and was appointed as Professor of Clinical Pharmacology at the University of Odense, Denmark. From 1976 to 1978 he had the same position at the University of Aarhus, Denmark. From 1978-2006 he was Professor and Chairman of the Department of Clinical Pharmacology, University of Lund, Lund, Sweden. He has been visiting professor at the Department of Obstetrics and Gynaecology, University of Toronto (1983-1985) and at the Department of Urology, University of Virginia, Charlottesville, USA (1997-1998), and is currently visiting professor at the University of Aarhus, Aarhus, Denmark (2013-2014). From 1993 to 2000 Dr. Andersson served as Vice Dean of the Medical Faculty at the University of Lund. He is a member of many international societies including the American Urological Association, the European Association of Urology, and the International Society for Sexual and Impotence Research. He is currently acting as section editor of Investigative Urology (Journal of Urology), Neurourology and Urodynamics, and World Journal of Urology, and serves on the Editorial Boards of several other journals including European Urology, International Journal of Impotence Research, International Journal of Urology, and LUTS. During his career, Dr. Andersson has authored more than 800 articles in peer-reviewed international journals.
SYNOPSIS OF AREA OF INTEREST: Dr. Andersson's research interests include urogenital and cardiovascular pharmacology and physiology, clinical trials, regenerative medicine and regenerative pharmacology.
DETAILED AREA OF INTEREST: Disturbances in urogenital tract function are common, and often based on malfunction of nerves and smooth muscle. Overactive bladder (OAB) syndrome is one of the most common disorders, and symptoms increase with age. Current drugs for treatment of OAB are limited by insufficient efficacy and side-effects, and new approaches are needed. Ongoing research includes the search for new targets to pharmacologically control bladder function and is specifically directed against ageing bladder dysfunction (including overactive and underactive bladder) and dysfunction caused by chronic pelvic ischemia. Stress urinary incontinence may be caused by urethral sphincter insufficiency, and the potential of using stem cells for treatment is presently explored. Erectile dysfunction (ED) is age-related and is found in 30% of men over 60 years. Although sildenafil is efficacious in the treatment for ED, limitations are noted in patient-categories such as diabetes and cardiovascular disease, where ED also is more prevalent. At WFIRM, the peripheral mechanisms involved in bladder overactivity and ED and afferent neuronal functions involved in the regulation of bladder, urethral, and erectile functions are studied to improve drug therapies and/or to identify new targets for pharmacological treatment. A wide variety of molecular biological techniques, functional in vitro methods, and in vivo models are used. These methods will also be applied to characterize pharmacological and physiological properties of engineered tissues in vitro and in vivo, with the purpose of identifying targets to pharmacologically modify their function.